Cholesterol

Regional Health is involved in cholesterol research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 718-2610.


ACCENTUATE: A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE).

PURPOSE: The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) and/or diabetes.

To learn more, contact:
Black Hills
Cardiovascular Research

4150 5th Street
Rapid City, SD

(605) 755-4326

Principal Investigator
Samuel Durr, MD, FACC
Cardiologist

REDUCE-IT: A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT).

PURPOSE: AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) being developed by Amarin Pharma Inc. for the treatment of hypertriglyceridemia. The purpose of this study is to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.

To learn more, contact:
Black Hills
Cardiovascular Research

4150 5th Street
Rapid City, SD

(605) 755-4326

Principal Investigator
Samuel Durr, MD, FACC
Cardiologist

STRENGTH: Outcomes Study to Assess Statin Residual Risk Reduction With EpaNova in High CV Risk patients With Hypertriglyceridemia (STRENGTH).

PURPOSE: The study is a randomized, double-blind, well-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and high risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for approximately 3-5 years as determined when the number of MACE outcomes is reached.

To learn more, contact:
Black Hills
Cardiovascular Research

4150 5th Street
Rapid City, SD

(605) 755-4326

Principal Investigator
Samuel Durr, MD, FACC
Cardiologist

EBBINGHAUS:Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS).

PURPOSE: This study evaluates change over time in neurocognitive testing in subjects receiving statin therapy in combination with evolocumab (AMG 145), compared with subjects receiving statin therapy in combination with placebo.

To learn more, contact:
Black Hills
Cardiovascular Research

4150 5th Street
Rapid City, SD

(605) 755-4326

Principal Investigator
Drew Purdy, MD FACC
Cardiologist

FOURIER:Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER).

PURPOSE: The primary hypothesis is that additional LDL-C lowering with Evolocumab (AMG 145) when used in addition to other treatment for dyslipidemia is well tolerated and decreases the risk of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary revascularization in subjects with clinically evident cardiovascular disease.

To learn more, contact:
Black Hills
Cardiovascular Research

4150 5th Street
Rapid City, SD

(605) 755-4326

Principal Investigator
Drew Purdy, MD FACC
Cardiologist

ODYSSEY OUTCOMES:Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727).

PURPOSE: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization) in patients who have experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and are treated with evidence-based medical and dietary management of dyslipidemia.

To learn more, contact:
Black Hills
Cardiovascular Research

4150 5th Street
Rapid City, SD

(605) 755-4326

Principal Investigator
Michael D'Urso, MD FACC
Cardiologist